All In Biotech

Drug Trial Radar · NCT05445154

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Jul 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Aug 31, 2021

Primary completion

Oct 31, 2024

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and tolerability of SKLB1028 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of SKLB1028 when given in combination with cytarabine/daunorubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia .

Conditions

  • Newly Diagnosed Acute Myeloid Leukemia (AML)

Interventions

  • SKLB1028 Dose EscalationDrug

    Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: up to Day42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.